These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 9850444)
21. [Effect of diltiazem on concentration of cyclosporin metabolites in Sandimmune and Neoral treated kidney transplant patients]. Sperschneider H; Wagner C; Korn A; Christians U Med Klin (Munich); 1997 Oct; 92(10):589-96. PubMed ID: 9446006 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, efficacy, and safety of Iminoral compared with Neoral in healthy volunteers and renal transplant recipients. Sayyah M; Argani H; Pourmand GR; Amini H; Ahmadiani A Transplant Proc; 2007 May; 39(4):1214-8. PubMed ID: 17524936 [TBL] [Abstract][Full Text] [Related]
23. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group. Pollak R; Wong RL; Chang CT Ther Drug Monit; 1999 Dec; 21(6):661-3. PubMed ID: 10604829 [TBL] [Abstract][Full Text] [Related]
24. Generic cyclosporine formulations: more open questions than answers. Cattaneo D; Perico N; Remuzzi G Transpl Int; 2005 Apr; 18(4):371-8. PubMed ID: 15773953 [TBL] [Abstract][Full Text] [Related]
25. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. van Mourik ID; Thomson M; Kelly DA Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413 [TBL] [Abstract][Full Text] [Related]
27. The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Qazi YA; Forrest A; Tornatore K; Venuto RC Clin Transplant; 2006; 20(3):313-7. PubMed ID: 16824147 [TBL] [Abstract][Full Text] [Related]
28. Conversion from Sandimmune to Neoral in organ transplant recipients. Bartucci MR; Bayer L; Brooks BK; Chandler L; Himes V; Meiergerd D; Newby B; Satmary NT; Shieck V J Transpl Coord; 1998 Dec; 8(4):227-33; quiz 234-5. PubMed ID: 10205463 [TBL] [Abstract][Full Text] [Related]
29. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related]
30. Conversion from Sandimmune to Neoral in stable heart transplant recipients. Pethig K; Ruhparwar A; Korn A; Christians U; Wahlers T Transplant Proc; 1996 Aug; 28(4):2287-9. PubMed ID: 8769228 [No Abstract] [Full Text] [Related]
31. Improvement of correlation between oral dose of cyclosporine and cyclosporinemia after substitution of cyclosporine standard presentation by cyclosporine microemulsion one, in 1345 patients with kidney transplantation. Spanish Sandimmune Neoral Conversion Group. Gentil Govantes MA; Gómez Ullate P; Errasti P; Fernández Fresnedo G; Capdevila L; Sanz Guajardo A; Cubero JJ Transplant Proc; 1998 Aug; 30(5):1658-9. PubMed ID: 9723231 [No Abstract] [Full Text] [Related]
32. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Keown P; Niese D Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620 [TBL] [Abstract][Full Text] [Related]
33. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration. Gaspari F; Anedda MF; Signorini O; Remuzzi G; Perico N J Am Soc Nephrol; 1997 Apr; 8(4):647-52. PubMed ID: 10495795 [TBL] [Abstract][Full Text] [Related]
34. Dose adjustment strategy for oral microemulsion formulation of cyclosporine: population pharmacokinetics-based analysis in kidney transplant patients. Tokui K; Kimata T; Uchida K; Yuasa H; Hayashi Y; Itatsu T; Nabeshima T Ther Drug Monit; 2004 Jun; 26(3):287-94. PubMed ID: 15167630 [TBL] [Abstract][Full Text] [Related]
35. Conversion from cyclosporine Sandimmune to cyclosporine Neoral in the stable renal transplant population. Griffin PJ; Moore RH; Jurewicz WA; Lord RH; Webley Y; Jenkins J Transplant Proc; 1997; 29(1-2):303. PubMed ID: 9123007 [No Abstract] [Full Text] [Related]
36. Conversion of stable renal transplant recipients from Sandimmune to Sang-35, a novel cyclosporine formulation, using a dose-normalized equivalence method. First MR; Weiskittel P; Burton M; Shah M; Dreyer D; Fleck P; Bey C; Peddi R; Canafax D; Schroeder TJ Transplant Proc; 1998 Aug; 30(5):1701-5. PubMed ID: 9723249 [No Abstract] [Full Text] [Related]